AHR and relapsing-remitting multiple sclerosis: Further evidence for the role of AhR in the regulation of CNS inflammation comes from studies showing decreased production of AhR ligands in relapsing-remitting MS patients and upregulation of these ligands during active disease [112], as well as the demonstration of the relevance of type I interferon-dependent signaling through AhR in astrocytes to reduce inflammation and disease severity in the EAE model [113].